HOME >> BIOLOGY >> NEWS
Early promise for treatment of Ebola

Preliminary findings of an animal study in this week's issue of THE LANCET suggest that scientists have taken an important step towards a possible treatment strategy for the deadly Ebola virus.

Haemorragic fever from the Ebola virus is fatal in up to 80%of cases in humans. The virus is thought to cause excessive blood coagulation and thrombosis leading to organ dysfunction. Inhibition of the blood coagulation pathway could therefore be a potential therapeutic approach for ebola treatment.

Thomas W Geisbert from the US Army Medical Research Institute of Infectious Diseases and colleagues injected 12 rhesus macaques with the ebola virus to induce the deadly ebola haemorragic fever. Nine of the macaques received an inhibitor of the blood coagulation pathway (called recombinant nematode anticoagulant protein c2, rNAPc2), while three macaques received the ebola virus only (the control group).

Treatment with rNAPc2 prolonged survival time and resulted in a 33% survival rate; this contrasted with macaques in the control group, of whom all except one died (since the study was completed the remaining control animal has also died). The surviving macaques in the treatment group were in good health nine months after the study. Survival was longer (12 days) for treated macaques who died compared with untreated macaques in the control group (8 days).

Thomas W Geisbert comments: "Our results have great clinical implications, since our treatment approach of Ebola haemorrhagic fever targets the disease process rather than replication of the infectious agent. Moreover, our findings raise the possibility that rNAPc2 could be useful in the treatment of other viral haemorrhagic fevers. Importantly, rNAPc2 has a suitable phamacokinetic and safety profile in human beings. The clinical efficacy of this treatment modality now needs to be proven."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
11-Dec-2003


Page: 1

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
4. Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects
5. Early predictor of breast cancer aggressiveness
6. Early treatment confirmed as key to stroke recovery
7. Early identification of kidney disease cost-effective only when directed at high-risk patients
8. Early treatment can prevent severe vision loss in premature infants
9. Early hominids may have behaved more human than we had thought
10. Early infection and rejection detection
11. Early-life environments shape development of stress behaviors and learning abilities in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/9/2019)... ... April 09, 2019 , ... The McLeod Center for ... following a rigorous and voluntary audit conducted by an independent, third-party panel of ... Novalis Certified Centers in the United States, McLeod is the only such cancer center ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of ... anchor tenant at the University’s newly created biotechnology park in Galway, Ireland. , ...
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem Cell is now ... Centers of Excellence. R3 wants patients to feel secure when they make a ... from Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... ... March 19, 2019 , ... ... hospital in Israel and the Middle East region, and Swiss-based CDMO Lonza ... manufacturing platform. The partnership will enable Sheba to vastly streamline its in-house ...
(Date:3/18/2019)... ... March 18, 2019 , ... For more than 15 years, ... solutions that allow life science companies to easily comply with FDA 21 CFR Part ... ™ is a managed service delivering end-to-end GxP compliance from vendor audit through ongoing ...
(Date:3/14/2019)... ... March 14, 2019 , ... EyeCRO LLC ... City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma Medical Research ... the fifth institution in Oklahoma to receive this prestigious endorsement. The award ...
(Date:3/14/2019)... ... March 14, 2019 , ... Open registration for ... the Full Spectrum of Case Management,” continues as CMSA makes plans to host ... the only case management industry conference serving the educational and networking needs of ...
Breaking Biology Technology:
Cached News: